"EMITEFURPTFDA9I50NF4AQ2" . "Emitefur"^^ . "C28H19FN4O8"^^ . "Pharmacologic Substance"^^ . "9I50NF4AQ2"^^ . "Last-FFBNCI" . . "C1022"^^ . . "110690-43-2"^^ . "An anticancer drug that belongs to the family of drugs called antimetabolites.NCI-GLOSS" . "C0053902"^^ . "Emitefur"^^ . "Organic Chemical"^^ . "emitefurPTNCI-GLOSSCDR0000045578" . "3-[[3-(Ethoxymethyl)-5-fluoro-3.6-dihydro-2,6-dioxo-1(2H0-pyrimidinyl]carbonyl]benzoic Acid 6-(Benzoyloxy)-3-cyano-2-pyridinyl EsterSNNCI" . "EmitefurPTNCI" . "An orally available antimetabolite composed of the 1-ethoxymethyl derivative of 5-fluorouracil (5-FU) and the dihydropyrimidine dehydrogenase (DPYD) inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar ratio, with antineoplastic activity. Upon administration, the prodrug emitefur is converted into 5-FU, while CNDP prevents the degradation of 5-FU by inhibiting DPYD and thereby prolonging the half-life of 5-FU. This increases 5-FU's concentration and thus its antitumor activity through inhibition of DNA and RNA synthesis, as well as inhibition of thymidylate synthase activity. In addition, by inhibiting the formation of 5-FU metabolites, some toxic effects associated with these metabolites may be reduced. DPYD is the rate-limiting enzyme in the catabolism of 5-FU.NCI" . "FDA"^^ . "Ethoxymethyl-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 6-(Benzoyloxy)-3-cyano-2-pyridinyl EsterSNNCI" . . . "BOF-A2CNNCI" . "Emitefur"^^ . "3-[3-(6-Benzoyloxy-3-cyrano-2-pyridyloxycarbonyl)benzoyl]-1-(ethoxymethyl)-5-fluorouracilSNNCI" . "(2) m-[[3-(Ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2H)-pyrimidinyl]carbonyl]benzoic Acid, 2-Ester with 2,6-Dihydroxynicotinonitrile Benzoate (Ester)SNNCI" .